Background: Filter and peak detection algorithms implemented in amplitude-integrated electroencephalogram (aEEG) systems are not standardized. New aEEG systems are continuously enriching the market and clinicians are faced with different aEEG devices whose tracings may vary. Objectives: The aim of this work was to determine the role of different aEEG systems on quantitative measurements of the aEEG. Methods: In this observational study, a single-channel aEEG recording (Olympic CFM 6000) with corresponding EEG signal was obtained from 32 infants at a gestational age of 36-44 weeks. The signals were split into 334 episodes of 4 h. New aEEG tracings were generated using the NicoletOne Reader Software and aEEG emulations with varying filter profiles and peak detection settings. The aEEG amplitude margins and automated annotation of continuous normal voltage (CNV) were compared. Results: The output of the Olympic and the NicoletOne systems are very similar but not identical; the Spearman rank correlations of the aEEG amplitude margins exceeded 0.9 and the differences in the lower and upper amplitude margins were 1.55 μV (SD 1.47) and -2.12 μV (SD 1.44) on average (n = 309), respectively. The aEEG emulation showed that the differences between the output of the Olympic and the NicoletOne system could be primarily ascribed to the peak detection algorithm. The differences in output can affect automated analyses with agreement rates in CNV detection of 76% (n = 32, positive) and 92% (n = 32, negative) when comparing the Olympic to the NicoletOne outputs. Conclusions: Commercial aEEG systems have similar but not identical outputs. Care is advised when interpreting automated aEEG classifications across different devices.

1.
Hellstrom-Westas L, Rosen I: Continuous brain-function monitoring: state of the art in clinical practice. Semin Fetal Neonatal Med 2006;11:503-511.
2.
Shah NA, Wusthoff CJ: How to use: amplitude-integrated EEG (aEEG). Arch Dis Child Educ Pract Ed 2015;100:75-81.
3.
Maynard D, Prior PF, Scott DF: Device for continuous monitoring of cerebral activity in resuscitated patients. Br Med J 1969;4:545-546.
4.
Burdjalov VF, Baumgart S, Spitzer AR: Cerebral function monitoring: a new scoring system for the evaluation of brain maturation in neonates. Pediatrics 2003;112:855-861.
5.
al Naqeeb N, Edwards AD, Cowan FM, Azzopardi D: Assessment of neonatal encephalopathy by amplitude-integrated electroencephalography. Pediatrics 1999;103:1263-1271.
6.
Olischar M, Klebermass K, Kuhle S, Hulek M, Kohlhauser C, Rucklinger E, Pollak A, Weninger M: Reference values for amplitude-integrated electroencephalographic activity in preterm infants younger than 30 weeks' gestational age. Pediatrics 2004;113:e61-e66.
7.
Hellström-Westas L: Continuous electroencephalography monitoring of the preterm infant. Clin Perinatol 2006;33:633-647.
8.
Vesoulis ZA, Paul RA, Mitchell TJ, Wong C, Inder TE, Mathur AM: Normative amplitude-integrated EEG measures in preterm infants. J Perinatol 2015;35:428-433.
9.
Olischar M, Klebermass K, Waldhoer T, Pollak A, Weninger M: Background patterns and sleep-wake cycles on amplitude-integrated electroencephalography in preterms younger than 30 weeks gestational age with peri-/intraventricular haemorrhage. Acta Paediatr 2007;96:1743-1750.
10.
Niemarkt HJ, Andriessen P, Peters CH, Pasman JW, Blanco CE, Zimmermann LJ, Bambang Oetomo S: Quantitative analysis of amplitude-integrated electroencephalogram patterns in stable preterm infants, with normal neurological development at one year. Neonatology 2010;97:175-182.
11.
Thorngate L, Foreman SW, Thomas KA: Quantification of neonatal amplitude-integrated EEG patterns. Early Hum Dev 2013;89:931-937.
12.
Quigg M, Leiner D: Engineering aspects of the quantified amplitude-integrated electroencephalogram in neonatal cerebral monitoring. J Clin Neurophysiol 2009;26:145-149.
13.
Quigg M, Leiner D: Limitations of single-channel EEG on the forehead for neonatal seizure detection. J Perinatol 2009;29:588.
14.
Wusthoff CJ, Shellhaas RA, Clancy RR: Limitations of single-channel EEG on the forehead for neonatal seizure detection. J Perinatol 2009;29:237-242.
15.
Dubowitz L, Ricciw D, Mercuri E: The Dubowitz neurological examination of the full-term newborn. Ment Retard Dev Disabil Res Rev 2005;11:52-60.
16.
Rosen I: The physiological basis for continuous electroencephalogram monitoring in the neonate. Clin Perinatol 2006;33:593-611.
17.
Toet MC, van Rooij LG, de Vries LS: The use of amplitude integrated electroencephalography for assessing neonatal neurologic injury. Clin Perinatol 2008;35:665-678.
18.
Zhang D, Ding H: Calculation of compact amplitude-integrated EEG tracing and upper and lower margins using raw EEG data. Health 2013;5:885-891.
19.
O'Reilly D, Navakatikyan MA, Filip M, Greene D, Van Marter LJ: Peak-to-peak amplitude in neonatal brain monitoring of premature infants. Clin Neurophysiol 2012;123:2139-2153.
20.
Viniker DA, Maynard DE, Scott DF: Cerebral function monitor studies in neonates. Clin Electroencephalogr 1984;15:185-192.
21.
Verma UL, Archbald F, Tejani NA, Handwerker SM: Cerebral function monitor in the neonate. I: normal patterns. Dev Med Child Neurol 1984;26:154-161.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.